Paul A. Lapchak

Guo-Yuan Yang

This book mainly discusses the current status of stroke transnational research and allows the reader to understand the interplay of common comorbidities in the stroke population such as diabetes and hypertension, and provides insight into stroke targets to promote cell survival, angiogenesis, neurogenesis, and most importantly, functional recovery after stroke. Throughout the world, stroke is still a leading cause of mortality and morbidity; each year approximately 15 million people worldwide suffer from stroke. Stroke is now the leading cause of death and disability in China. Large communities of stroke survivors are eagerly awaiting scientific advances in transnational stroke research that would offer neuroprotective therapeutics for acute stroke management, or rehabilitation and regenerative strategies utilizing novel stem cell-based approaches. While research is ongoing, the Editors have compiled this volume to help the further understanding of the pathophysiology of stroke and to review and identify future potential biomarkers. The book is written for students, researchers and physicians in neurosciences, neurology and neuroradiology.

Translational Research in Stroke

John H. Zhang

This volume sets a basis for effective translational research. Authored by experts in the field of translational stroke research, each chapter specifically addresses one or more components of preclinical stroke research. The emphasis is placed on target identification and drug development using state-of-the-art in vitro and in vivo assays, in combination with in vitro toxicology assays, AMDE and clinical design.

From Target Selection to Clinical Trials

Translational Stroke Research

A critical and comprehensive look at current state-of-the-art scientific and translational research being conducted internationally, in academia and industry, to address new ways to provide effective treatment to victims of ischemic and hemorrhagic stroke and other ischemic diseases. Currently stroke can be successfully treated through the administration of a thrombolytic, but the therapeutic window is short and many patients are not able to receive treatment. Only about 30% of patients are "cured" by available treatments. In 5 sections, the proposed volume will explore historical and novel neuroprotection mechanisms and targets, new and combination therapies, as well as clinical trial design for some of the recent bench-side research.

Paul A. Lapchak

Books

Your next favorite book is out there